Podcast Summary: The Interview (BBC World Service)

Episode: Dr Aaron Motsoaledi, South African Health Minister: The fight against HIV/AIDS continues.

Host: Mahoney Jones (BBC Africa Correspondent)
Date: February 9, 2026

Overview

This episode features an in-depth conversation with Dr. Aaron Motsoaledi, the South African Health Minister, who discusses the country’s urgent response to sudden US foreign aid cuts, the evolving landscape of HIV/AIDS treatment and research in South Africa, and the push toward national self-sufficiency in healthcare financing. The conversation explores the impact of lost funding on programs and research, innovative responses by the government and partners, and hopes for the rollout of a promising new HIV medication.

Key Discussion Points & Insights

1. The Impact of US Funding Cuts on HIV/AIDS Programs

Background:

• In 2025, the US abruptly froze foreign aid, including significant contributions to the President’s Emergency Plan for AIDS Relief (PEPFAR), impacting HIV/AIDS services globally, and particularly in South Africa—the largest beneficiary.
• This move caused medical supply shortages, confusion, and the closure of some clinics.

Key Quotes:

• “This is a matter of life and death.” – HIV Charity Representative (02:06)
• “It is reasonable for the United States to want to reduce its funding over time. But the sudden withdrawal of life saving support is having a devastating impact...” – Winnie Byanyima, head of UNAIDS (03:10)

Dr. Motsoaledi’s Response:

• Dr. Motsoaledi called the funding crisis “a wake up call for Africa,” emphasizing the need for countries to build self-sufficient health systems (03:43).
• He criticized new US policies requiring countries to share pathogen data and genomes in exchange for funding: “No nation on earth that respect itself should accede to that.” (05:34)

2. Emergency Measures and Future Funding Strategy

Immediate Response:

• The South African Minister of Finance authorized R750 million in emergency funding, approved by Parliament, to fill critical gaps previously covered by US aid (06:56).

Priorities Funded:

• Hiring data capturers (those responsible for recording HIV testing and treatment data), research support, and recruitment of lay counselors (08:03).

Self-sufficiency & National Health Insurance (NHI):

• Dr. Motsoaledi reiterated the importance of universal health coverage, or NHI, to lessen foreign dependence:
  “When I call for universal health coverage… it’s a call for self-sufficiency, that local resources must be mobilized so that you don’t depend on anybody.” (04:07)

3. The State of HIV Research Post-Funding Cut

A Bleak Outlook—& New Partnerships:

• Research institutions relying on US funding were “worse off… obviously,” but the Bill & Melinda Gates Foundation and the Wellcome Trust committed new contributions on the condition of co-funding from South Africa's Treasury (08:27).

  “There’s going to be R600 million provided… to make sure that research does not collapse in the country.” (08:44)

Global Significance:

• Dr. Motsoaledi emphasized that HIV research in South Africa benefits not just the country but the whole world, especially US pharmaceutical firms (09:46).

  “Once that vaccine becomes available, it’s not available for South Africa. The pharmaceutical companies… are likely to be American pharmaceutical companies.” (10:52)

4. The Pepfar “Bridge” and the Search for Sustainability

Uncertainty Remains:

• A 6-month bridge from PEPFAR is set to expire in March. Dr. Motsoaledi expects it will not be extended and questions the desirability of continued dependence due to strings attached and misaligned priorities (11:59).

  “…It is funding, it is help. But it’s also problematic because it’s not in fitting in with our programs…” (12:47)

Future Planning:

• The Treasury is tasked with ensuring sustainable domestic funding. Dr. Motsoaledi acknowledged Parliament’s alignment with this goal but noted it may take time to integrate into the budget process. (13:40)

5. Achievements & New Initiatives: Three Pillars to Ending the Epidemic

ARV Rollout—From Survival to Ambition:

• Under Dr. Motsoaledi's prior leadership, ARV access vastly expanded. He now urges the end of complacency:

  “We must not accept… we are going to live with the pandemic called HIV/AIDS forever. We must think about bringing it to an end.” (18:22)

Major initiatives:

• Close the Gap Campaign: Targets improving the middle “95” of the UN 95-95-95 goal (the % of diagnosed people on treatment).

  • South Africa stands at 96-79-94; the biggest challenge is getting HIV-positive individuals onto treatment.
  • Campaign aims to find and treat 1.1 million more people. (18:55)

• Lenacapavir Rollout: A new long-acting HIV prevention drug to become affordable for low/middle income countries by 2027.

  • The initial launch will reach 488,000 people at 350 clinics due to supply limitations (20:52, 21:26).
  • Generics will reduce costs from $128 to $40 per dose, expected by next year following voluntary licensing deals brokered globally (22:10).

• Integrated HIV/TB Screening: Major campaign to screen 5 million people for TB, reflecting the strong links between the diseases (19:50).

6. Challenges & Long-term Vision

On Scaling Up:

• Initial supplies of lenacapavir are limited, but Dr. Motsoaledi is undaunted:

  “There’s no program that started 100%...We started with one and went upwards… A journey of a thousand miles starts with the first step. So we are taking the first steps.” (23:52)

Global Solidarity Still Needed:

• While South Africa moves towards independence, global cooperation and funding remain crucial to contain pandemics that “do not know borders.” (04:07, 13:40)

Notable Quotes & Memorable Moments

• Dr. Motsoaledi’s candor:
  “You are asking me to convince a lion to become a vegetarian. It’s a very difficult job.” (11:38)
• On voluntary licensing and generics:
  “Sense has prevailed. Voluntary license[s] have been given, I think, to about seven pharmaceutical companies.” (22:40)

Timestamps of Key Segments

• [02:06] – HIV Charity perspectives on funding cuts
• [03:10] – UNAIDS head Winnie Byanyima’s warning
• [04:07] – Motsoaledi on universal health coverage and self-sufficiency
• [06:56] – Emergency funding mechanisms explained
• [08:27–10:52] – Research funding, global partnerships & vaccine trials
• [11:59] – The PEPFAR bridge and dilemmas of aid
• [13:40] – Domestic funding ambitions
• [18:22] – Motsoaledi’s vision for “ending” HIV/AIDS
• [19:50–23:52] – New initiatives: Close the Gap, lenacapavir rollout, and generics

Conclusion

This episode gives listeners a candid insider’s view of the pressures, progress, and prognosis for South Africa’s—and, by extension, the world’s—fight against HIV/AIDS in a new era. Dr. Motsoaledi stresses both the importance of national responsibility and the inescapable necessity of global solidarity in public health.

For further conversations, search “The Interview” on the BBC podcast platform.